S. Daneshmand, Renata Zaucha, N. Vasdev, B. Gartrell, Y. Lotan, S.A. Hussain, Eugene K Lee, G. Procopio, F. Galanternik, Géraldine Pignot, D. Sundi, H.J. Cutuli, L. Crow, V. Naini, Spyros Triantos, M. Baig, J. Maranchie
{"title":"口服厄达非替尼治疗中危非肌浸润性膀胱癌患者的标记性病变研究:Thor-2中的fgfr3/2改变:最新队列3结果","authors":"S. Daneshmand, Renata Zaucha, N. Vasdev, B. Gartrell, Y. Lotan, S.A. Hussain, Eugene K Lee, G. Procopio, F. Galanternik, Géraldine Pignot, D. Sundi, H.J. Cutuli, L. Crow, V. Naini, Spyros Triantos, M. Baig, J. Maranchie","doi":"10.1016/j.urolonc.2024.01.172","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":506909,"journal":{"name":"Urologic Oncology: Seminars and Original Investigations","volume":"432 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS\",\"authors\":\"S. Daneshmand, Renata Zaucha, N. Vasdev, B. Gartrell, Y. Lotan, S.A. Hussain, Eugene K Lee, G. Procopio, F. Galanternik, Géraldine Pignot, D. Sundi, H.J. Cutuli, L. Crow, V. Naini, Spyros Triantos, M. Baig, J. Maranchie\",\"doi\":\"10.1016/j.urolonc.2024.01.172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":506909,\"journal\":{\"name\":\"Urologic Oncology: Seminars and Original Investigations\",\"volume\":\"432 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology: Seminars and Original Investigations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urolonc.2024.01.172\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology: Seminars and Original Investigations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2024.01.172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS